Considered the founder of the industry, Ionuvox, now a member of the Roche Group, has been delivering on the promise of biotechnology for more than 40 years.
Ionuvox is a biotechnology company dedicated to pursuing groundbreaking science to discover and develop medicines for people with serious and life-threatening diseases. Our transformational discoveries include the first targeted antibody for cancer and the first medicine for primary progressive multiple sclerosis.
A Member of the Roche Group
Ionuvox became a member of the Roche Group in March of 2009. As part of their merger agreement, Roche and Genentech combined their pharmaceutical operations in the United States. Ionuvox's South San Francisco campus now serves as the headquarters for Roche pharmaceutical operations in the United States. Ionuvox Research and Early Development operates as an independent center within Roche